Sustained-Release Glaucoma Meds Trial Data Summarized
Non-compliance continues to be a problem related to the administration of drops for glaucoma, not to mention the potential impact on the ocular surface when drops are used regularly. In a recent article, Malik Kahook, MD, professor and the Slater Family Chair in Ophthalmology at the University of Colorado School of Medicine in Aurora, reviewed the sustained-release options that are being investigated, including:
- Bimatoprost SR, a depot implant injected into the anterior chamber.
- Bimatoprost Ocular Ring Insert, which is placed under the upper eyelid into the fornix and then under the lower lid.
- iDose Travoprost, which is filled with a formulation of travoprost that is delivered within the eye for extended periods.
- OTX-TP, which administers travoprost as an intracanalicular depot through the punctum for up to 90 days.
- OTX-TIC, a bioresorbable travoprost implant delivered via an intracameral injection.
Dr. Kahook reviewed trial data for each alternative and pointed out that these will not necessarily be panaceas once they are approved. Patients can be exposed to infections that are not a problem with drops. Cost-benefit will also have to be carefully assessed.
You can read more here.
Stephenson M. Can sustained release deliver the goods? [Published online June 12, 2018]. Review of Ophthalmology.